Development of early diagnostic and therapeutic methods useful for buruli ulcer control
| Project/Area Number |
23591664
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
NAKANAGA Kazue 国立感染症研究所, ハンセン病研究センター・感染制御部, 主任研究官 (40183884)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
星野 仁彦 国立感染症研究所ハンセン病研究センター, 感染制御部, 室長 (20569694)
石井 則久 国立感染症研究所, ハンセン病研究センター, センター長 (50159670)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
石井 則久 国立感染症研究所ハンセン病研究センター, センター長 (50159670)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | buruli ulcer / Mycobacterium ulcerans / M. shinshuense / マイコラクトン / M. pseudoshotosii / MPM / M. marinum / M. shigaense |
|---|
| Research Abstract |
Buruli ulcer (BU) is a necrotizing skin disease caused by Mycobacterium ulcerans. BU is an important emerging human disease, which mainly affects the extremities among immunocompetent individuals. BU has been reported in at least 33 countries, and M. ulcerans disease is probably the third most common mycobacterial disease after tuberculosis and leprosy. BU is categorized as a neglected tropical disease by the World Health Organization (WHO). It is most endemic in sub-Saharan Africa; however, it has been reported worldwide, including in some non-tropical areas.
Although only a few reports in Asia before, ``M. ulcerans subsp. shinshuense'' is proposed as a subspecies of M. ulcerans by our reports. We have collected a total of 50 BU cases (male 17 cases, female 33 cases) as of March 2014. We have established new PCR and specimen transporting method which is useful for BU control. Moreover, we have clarified the therapeutic effect of combination therapy with 3 medicines.
|
Report
(4 results)
Research Products
(125 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Bacteremia due to Mycobacterium massilinese in a patient with chronic myelogenous leukemia : case report2012
Author(s)
Hamamoto T, Yuki A, Naoi K, Kawakami S, Banba Y, Yamamura T, Hikota R, Watanabe J, Kimura F, Nakanaga K, Hoshino Y, Ishii N, Shimazaki H, Nakanishi K, Tamai S
-
Journal Title
Diagnostic Microbiology and Infectious Disease
Volume: 74
Pages: 183-185
Related Report
-
[Journal Article]2012
Author(s)
Morimoto K, Yoshiyama T, Okumura M, Hoshino Y, Yoshimori K, Ogata H, Kurashima A, Gemma A, Kudoh S
-
Journal Title
Intern Med
Volume: 51
Pages: 3435-3437
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Usefulness Of Biomarkers (Glycopeptidolipid Core IgA Antibody, CD64 On Neutrophils, Cathelicidin, And Vitamin D) And Radiologic Score (NICE Score) In MAC Pulmonary Disease2013
Author(s)
Morimoto K, Hoshino Y, Sasaki Y, Yoshiyama T, Sakakibara Y, Ogata H, Kudoh S, Kurashima A
Organizer
The 108th International Conference of American Thoracic Society
Place of Presentation
San Diego USA
Related Report
-
-
-
-
-
-
-
[Presentation] Usefulness Of Biomarkers (Glycopeptidolipid Core IgA Antibody, CD64 On Neutrophils, Cathelicidin, And Vitamin D) And Radiologic Score (NICE Score) In MAC Pulmonary Disease.2013
Author(s)
Morimoto K, Hoshino Y, Sasaki Y, Yoshiyama T, Sakakibara Y, Ogata H, Kudoh S, Kurashima A.
Organizer
The 108th International Conference of American Thoracic Society
Place of Presentation
San Diego USA
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
